Bleharski Joshua 4

What Happened Joshua Bleharski, a director of Scribe Therapeutics (SCTX), was granted a derivative award of 14,725 shares (reported as $0.00 per share) on July 23, 2026. The filing classifies the transaction as an award/grant (code A) rather than an open‑market purchase or sale, so no cash changed hands at the time of grant.

Key Details

• Transaction date: 2026-07-23; Form 4 filed: 2026-07-27 (filed within the standard 2-business-day window).
• Award type: Derivative award reported (footnote indicates these are options).
• Amount: 14,725 shares (reported acquisition amount); price shown: $0.00; aggregate value reported: $0.
• Vesting: Options vest 1/3 on each of July 23, 2027, 2028 and 2029, conditioned on continued service (per footnote).
• Shares owned after transaction: Not specified in the provided filing.

Context This is a time‑based equity grant to a company director as part of compensation, not a market purchase or sale. Vesting over three years means the award converts to exercisable options (or becomes owned) only if the director remains in service on each vesting date. Such grants are common for board compensation and do not by themselves indicate a buy/sell decision.